Oncology and Hematology - Prova Education

209-224 of 246

Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer
Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer
Oncology and Hematology
Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer
SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer
SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer
Oncology and Hematology
SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer
TAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1
TAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1
Oncology and Hematology
TAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1
TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
Oncology and Hematology
TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
Real-World Sequencing and Survival in Locally Advanced Prostate Cancer
Real-World Sequencing and Survival in Locally Advanced Prostate Cancer
Oncology and Hematology
Real-World Sequencing and Survival in Locally Advanced Prostate Cancer
Updates from Apa-RP: Apalutamide and ADT in High-Risk Localized Prostate Cancer
Updates from Apa-RP: Apalutamide and ADT in High-Risk Localized Prostate Cancer
Oncology and Hematology
Updates from Apa-RP: Apalutamide and ADT in High-Risk Localized Prostate Cancer
Evolving Trends in Germline Genetic Testing for Prostate Cancer
Evolving Trends in Germline Genetic Testing for Prostate Cancer
Oncology and Hematology
Evolving Trends in Germline Genetic Testing for Prostate Cancer
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
CME/CE
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
Meghan Mooradian, MD
0.25 credits
- Meghan Mooradian, MD
0.25 credits
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
CME/CE
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Benjamin Levy, MD; Alexander Spira, MD, PhD, FACP
0.25 credits
- Benjamin Levy, MD
- Alexander Spira, MD, PhD, FACP
0.25 credits
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
CME/CE
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
Jyoti Patel, MD; Pasi Antero Jänne, MD, PhD
0.50 credits
- Jyoti Patel, MD
- Pasi Antero Jänne, MD, PhD
0.50 credits
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
CME/CE
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Helena Yu, MD
0.25 credits
- Helena Yu, MD
0.25 credits
Advances in Minimally Invasive Screening for Lung Cancer
Advances in Minimally Invasive Screening for Lung Cancer
CME/CE
Advances in Minimally Invasive Screening for Lung Cancer
Julie A. Barta, MD, ATSF; Peter J. Mazzone, MD, MPH, FCCP
0.25 credits
- Julie A. Barta, MD, ATSF
- Peter J. Mazzone, MD, MPH, FCCP
0.25 credits
Treatment Options for Invasive Fungal Infections: Why They Don't Always Work
Treatment Options for Invasive Fungal Infections: Why They Don't Always Work
CME/CE
Treatment Options for Invasive Fungal Infections: Why They Don't Always Work
Thomas F. Patterson, MD, FACP, FIDSA; George Thompson III, MD, FIDSA
- Thomas F. Patterson, MD, FACP, FIDSA
- George Thompson III, MD, FIDSA
Invasive Fungal Infections: More Common Than You Think
Invasive Fungal Infections: More Common Than You Think
CME/CE
Invasive Fungal Infections: More Common Than You Think
Peter G. Pappas, MD, FACP; Thomas F. Patterson, MD, FACP, FIDSA
- Peter G. Pappas, MD, FACP
- Thomas F. Patterson, MD, FACP, FIDSA
Insights from the Latest Clinical Trials in Lung Cancer
Insights from the Latest Clinical Trials in Lung Cancer
CME/CE
Insights from the Latest Clinical Trials in Lung Cancer
Mark Socinski, MD; Tarek M. Mekhail, MD, MSC, FRCSI, FRCSEd
0.25 credits
- Mark Socinski, MD
- Tarek M. Mekhail, MD, MSC, FRCSI, FRCSEd
0.25 credits
Tenosynovial Giant Cell Tumor (TGCT): New Perspectives on Advances in Treatment
Tenosynovial Giant Cell Tumor (TGCT): New Perspectives on Advances in Treatment
CME/CE
Tenosynovial Giant Cell Tumor (TGCT): New Perspectives on Advances in Treatment
William D. Tap, MD; Silvia Stacchiotti, MD
0.25 credits
- William D. Tap, MD
- Silvia Stacchiotti, MD
- Michiel van de Sande, MD, PhD
- Andrew J. Wagner, MD, PhD
0.25 credits

14/8